Estimating medication persistency using administrative claims data

American Journal of Managed Care

Volumn 11, Issue 7, 2005, Pages 449-457

  Sikka, Rishi ^a,b   Xia, Fang ^a   Aubert, Ronald E ^a,c  

^a Medco Health Solutions ^*  (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c Medco Health Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOMATION; CALCULATION; DATA ANALYSIS; DRUG USE; DRUG UTILIZATION; HEALTH INSURANCE; HUMAN; MEASUREMENT; MEDICATION PERSISTENCY; MEDLINE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SURVIVAL;

HUMANS; PATIENT COMPLIANCE; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SERVICES; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 22544468809     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Kennedy JJ, Coyne JS, Sclar DA. Drug affordability and prescription noncompliance in the United States: 1997-2002. Clin Ther. 2004;26:607-614.
2. Sclar DA, Chin A, Skaer TL, Okamoto MP, Nakahiro RK, Gill MA. Effect of health education in promoting prescription refill compliance among patients with hypertension. Clin Ther. 1991;13:489-495.
3. Sclar DA, Skaer TL, Chin A, Okamoto MP, Gill MA. Utility of a transdermal delivery system for antihypertensive therapy. Part 2. Am J Med. 1991;91:57S-60S.
4. Skaer TL, Sclar DA, Markowski DJ, Won JKH. Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures-a study of patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther. 1993;18:295-299.
5. Skaer TL, Sclar DA, Markowski DJ, Won JKH. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens. 1993;7:515-518.
6. Skaer TL, Sclar DA, Markowski DJ, Won JKH. Utility of a sustained-release formulation for antihypertensive therapy. J Hum Hypertens. 1993;7:519-522.
7. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res. 1995;23:395-412.
8. Okano GJ, Rascati KL, Wilson JP, Remund DD, Grabenstein JD, Brixner DI. Patterns of antihypertensive use among patients in the US Department of Defense database initially prescribed an angiotensin-converting enzyme inhibitor or calcium channel blocker. Clin Ther. 1997;19:1433-1445.
9. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
10. Hurley JS, Frost EJ, Trinkaus KM, Buatti MC, Emmett KE. Relationship of compliance with hormone replacement therapy to short-term healthcare utilization in a managed care population. Am J Manag Care. 1998;4:1691-1698.
11. Blanford L, Dans PE, Ober JD, Wheelock C. Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. J Manag Care Pharm. 1999;5:47-51.
12. Roe CM, Motheral BR, Teitelbaum F, Rich MW. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J. 1999;138:818-825.
13. Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: the influence of age, gender, and race. Diabetes Educ. 1999;25:531-538.
14. Lawrence M, Guay DRP, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 2000;20:470-475.
15. Xuan J, Duong PT, Russo PA, Lacey MJ, Wong B. The economic burden of HH congestive heart failure in a managed care population. Am J Manag Care. 2000;6:693-700.
16. Urquhart J. Some economic consequences of noncompliance. Curr Hypertens Rep. 2001;3:473-480.
17. Dezii CM. Persistency with drug therapy: a practical approach using administrative claims data. Manag Care. 2001;10(2):42-45.
18. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
19. Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr Hypertens Rep. 2002;4:424-433.
20. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther. 2003;25:2307-2335.
21. Dusing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep. 2001;3:488-492.
22. Metry J-M. Measuring compliance in clinical trials and ambulatory care. In: Metry J-M, Meyer UA, eds. Drug Regimen Compliance. Issues in Clinical Trials and Patient Management. New York: John Wiley & Sons; 1999:1-22.
23. Reardon G, Schwarz GF, Mozaffari E, Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137(suppl):S3-S12.
24. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1997;19:1446-1457.
25. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther. 2002;24:1347-1357.
26. Kopjar B, Sales AEB, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol. 2003;92:1106-1108.
27. Esposti LD, Di Martino M, Saragoni S, et al. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J Clin Hypertens (Greenwich). 2004;6(2):76-82.
28. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J. 2003;145:438-444.
29. Perwien A, Hall J, Swensen A, Swindle R. Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/ hyperactivity disorder. J Manag Care Pharm. 2004;10:122-129.
30. Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New jersey cohorts. Health Serv Res. 1995;30:593-614.
31. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
32. Crystal S, Sambamoorthi U, Moynihan PJ, McSpiritf E. Initiation and continuation ation of newer antiretroviral treatments among Medicaid recipients with AIDS. J Gen Intern Med. 2001;16:850-859.
33. Pilote L, Beck C, Richard H, Eisenberg MJ. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ. 2002;167:246-252.
34. Verdamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC. Treatment strategies, persistence of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003;44:539-545.
35. Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care. 2002;8(suppl):S249-S254.
36. Caro JJ. Stepped care for hypertension: are the assumptions valid? J Hypertens Suppl. 1997;15(7):S35-S39.
37. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther. 1998;20:671-681.
38. Caro JJ, Speckman JL. Existing treatment strategies: does noncompliance make a difference? J Hypertens Suppl. 1998:16(7):S31-S34.
39. Fairman KA, Drevets WC, Kresiman JJ, Teitelbaum F. Course of antidepressant treatment, drug type, and prescriber's specialty. Psychiatr Serv. 1998;49:1180-1186.
40. Caro JJ, Salas MM, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31-37.
41. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160:41-46.
42. Ostrop NJ, Gill MJ. Antiretroviral medication adherence and persistence with respect to adherence tool usage. AIDS Patient Care STDS. 2000;14:351-358.
43. Boccuzzi SJ, Wogen J, Fox J, Sung JCY, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care. 2001;24:1411-1415.
44. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther. 2001;23:1999-2010.
45. Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18:649-656.
46. Kotzan JA, Martin BC, Wade WE. Persistence with estrogen therapy in a post-menopausal Medicaid population. Pharmacotherapy. 1999;19:363-369.
47. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9(9 suppl):2-6.
48. Sheehy O, LeLorier J. Patterns of amlodipine and felodipine use in an elderly Quebec population. Can J Cardiol. 2000;16:1109-1117.
49. Catalan VS, Couture JA, LeLorier J. Predictor of persistence of use of the novel antidiabetic agent acarbose. Arch Intern Meet. 2001;161:1106-1112.
50. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23:1311-1320.
51. Pilon D, Castilloux AM, LeLorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol. 2001;97:97-100.
52. Becker SL, Dezii CM, Burtcel B, Kawabata H, Hodder S. Young HIV-infected adults are at greater risk for medication nonadberence. MedGenMed. 2002;4(3):21.
53. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemia therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res. 2002;30:71-79.
54. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistence rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 2002;8(suppl):S255-S261.
55. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68-71.
56. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16:569-575.
57. Larsen J, Andersen M, Kragstrup J, Gram LF. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol. 2002;53:375-378.
58. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care. 2002;8(suppl):S271-S277.
59. Abraha I, Monledori A, Stracci F, Rossi M, Romagnoli C. Statin compliance in the Umbrian population. Eur J Clin Pharmacol. 2003;59:659-661.
60. Aubert RE, Fulop G, Xia F, Thiel M, Maldonato D, Woo C. Evaluation of a depression health management program to improve outcomes in a first or recurrent episode depression. Am J Manag Care. 2003;9:374-380.
61. Moride Y, Ducruet T, Rochon S, Lavoie F. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology (Oxford). 2003;42(suppl 3):iii17-iii22.
62. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther. 2003;25:1172-1185.
63. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol. 2003;13(suppl 4):S44-S52.
64. Wogen J, Kreilick CA, Livornese RC, Yokoyama K, Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm. 2003;9:424-429.
65. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol. 2004;137(suppl):S13-S16.